News
 

Source: JAMA. 2021;325(4):373-381. doi:10.1001/jama.2020.25071

Whether anti-seizure medication (ASM) increases the risk for cancer has been debated for decades. While for some ASM, a carcinoma-promoting effect has been suspected, carcinoma-protective effects have been shown for other ASM. However, the issue remains unresolved as data from preclinical and clinical studies have been inconsistent and...

A new study suggests that the virus might actually damage the brain's small blood vessels rather than nerve cells themselves.

Atabecestat, a nonselective oral β-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease. Preliminary analyses suggested dose-related cognitive worsening and neuropsychiatric adverse events (AEs).

A new research study (EXPAND) has been conducted to investigate the effects of siponimod on cognitive processing speed in patients with secondary progressive (SP) multiple sclerosis (MS).

The first blood test to detect the presence of amyloid, a hallmark of Alzheimer's disease (AD), is now available for clinical use, the company behind the test's development, C2N Diagnostics, has announced. The availability of the noninvasive, easily administered test is being called a milestone in the early detection and diagnosis of AD.

Apathy is an early marker of frontotemporal dementia (FTD) and predicts future cognitive decline, a new study has shown.

Focused ultrasound for ablation of the subthalamic nucleus in one hemisphere improved motor features in a selected group of patients with markedly asymmetric Parkinson's disease, but was associated with a high rate of adverse events, including dyskinesias and other neurologic complications, in a new randomized sham-controlled trial published online...

In a new article ( Murueta‐Goyena, A., Del Pino, R., Galdós, et al. (2020), Retinal thickness predicts the risk of cognitive decline in Parkinson's disease. Ann Neurol doi:10.1002/ana.25944) the researchers analyzed longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's...

Neutrophil granulocyte biomarkers can distinguish between neuromyelitis optica spectrum disorders (NMOSD) and anti-MOG antibody-associated disease (MOGAD) on one hand and multiple sclerosis (MS) on the other hand.